Edition:
United States

Eyenovia Inc (EYEN.OQ)

EYEN.OQ on NASDAQ Stock Exchange Capital Market

2.81USD
17 Jan 2019
Change (% chg)

-- (--)
Prev Close
$2.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
11,766
52-wk High
$10.60
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Eyenovia Prices Public Offering Of Common Stock
Wednesday, 19 Dec 2018 09:05am EST 

Eyenovia Inc ::EYENOVIA PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.20 MILLION COMMON SHARES PRICED AT $2.45PER SHARE.  Full Article

Eyenovia Files For Offering Of Up To 1.2 Mln Of Shares Of Common Stock
Wednesday, 12 Dec 2018 04:52pm EST 

Dec 12 (Reuters) - Eyenovia Inc ::EYENOVIA INC FILES FOR OFFERING OF UP TO 1.2 MILLION OF SHARES OF OUR COMMON STOCK - SEC FILING.  Full Article

Eyenovia reports third quarter results
Tuesday, 13 Nov 2018 06:30am EST 

Nov 13 (Reuters) - Eyenovia Inc ::EYENOVIA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.43.Q3 EARNINGS PER SHARE VIEW $-0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

Eyenovia Reports Q1 Loss Per Share Of $0.45
Wednesday, 9 May 2018 06:30am EDT 

May 9 (Reuters) - Eyenovia Inc ::EYENOVIA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND COMPLETION OF EYN PG21 STUDY.Q1 LOSS PER SHARE $0.45.  Full Article

Eyenovia Announces Appointment Of John Gandolfo As CFO
Tuesday, 9 Jan 2018 08:00am EST 

Jan 9 (Reuters) - Eyenovia Inc ::EYENOVIA INC - APPOINTMENT OF JOHN GANDOLFO AS CHIEF FINANCIAL OFFICER EFFECTIVE DECEMBER 18, 2017.EYENOVIA ANNOUNCES APPOINTMENT OF JOHN GANDOLFO AS CHIEF FINANCIAL OFFICER.  Full Article

Eyenovia Sees IPO Of 2.73 Mln Shares Of Common Stock Priced Between $10-$12 Per Share
Tuesday, 9 Jan 2018 07:00am EST 

Jan 9 (Reuters) - Eyenovia Inc ::EYENOVIA INC SEES IPO OF 2.73 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $10.00 AND $12.00 PER SHARE - SEC FILING.EYENOVIA SAYS INTENDS TO USE IPO PROCEEDS TOGETHER WITH EXISTING CASH, ABOUT $12 MILLION TO COMPLETE PHASE III CLINICAL TRIALS FOR MICROPROST.EYENOVIA SAYS INTENDS TO USE IPO PROCEEDS TOGETHER WITH EXISTING CASH, ABOUT $2 MILLION TO COMPLETE PHASE III CLINICAL TRIALS FOR MICROSTAT.EYENOVIA SAYS INTENDS TO USE IPO PROCEEDS TOGETHER WITH EXISTING CASH, ABOUT $1.5 MILLION TO COMPLETE MICROTEARS REGISTRATION ACTIVITIES.  Full Article